Skip to main content

Table 3 Predictors of subsequent treatment for non-transplant and transplant patients with NDMM

From: Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

  Non-transplant patients
Overall (N = 22,062) 6+ months follow-upa (n = 14,866) 12+ months follow-upa (n = 11,619) 24+ months follow-upa (n = 7233)
Predictors of subsequent treatment (receiving LOT2+ vs. only LOT1) Odds ratiob (95% CI) P-valueb Odds ratiob (95% CI) P-valueb Odds ratiob (95% CI) P-valueb Odds ratiob (95% CI) P-valueb
Age at MM diagnosis, years
 < 65 0.90 (0.84–0.97) 0.0035 1.01 (0.92–1.11) 0.7975 1.09 (0.98–1.22) 0.1154 1.08 (0.94–1.25) 0.2889
 65–74 Reference Reference Reference Reference
 75–84 0.86 (0.80–0.91) < 0.0001 0.84 (0.77–0.90) < 0.0001 0.86 (0.78–0.94) 0.0010 0.91 (0.80–1.03) 0.1173
 ≥ 85 0.47 (0.42–0.53) < 0.0001 0.45 (0.40–0.52) < 0.0001 0.44 (0.38–0.52) < 0.0001 0.55 (0.44–0.69) < 0.0001
Sex, male 0.96 (0.91–1.01) 0.1494 1.03 (0.96–1.10) 0.3843 1.08 (1.00–1.17) 0.0509 1.10 (0.99–1.22) 0.0871
Comorbidities during 180 days prior to index MM diagnosis
 Cardiovascular disordersc 0.84 (0.79–0.90) < 0.0001 0.84 (0.78–0.91) < 0.0001 0.83 (0.76–0.91) < 0.0001 0.88 (0.78–1.00) 0.0479
 Liver disease 0.91 (0.80–1.04) 0.1573 0.88 (0.75–1.03) 0.1195 0.88 (0.72–1.06) 0.1784 0.73 (0.57–0.94) 0.0149
 Pulmonary circulation disorders 0.75 (0.66–0.86) < 0.0001 0.76 (0.64–0.89) 0.0009 0.75 (0.62–0.91) 0.0030 0.79 (0.60–1.04) 0.0924
 Renal impairment 0.91 (0.85–0.98) 0.0112 0.91 (0.83–0.99) 0.0225 0.97 (0.88–1.07) 0.5209 0.94 (0.82–1.07) 0.3363
  Transplant patients
Overall (N = 2763) 6+ months follow-upa (n = 2595) 12+ months follow-upa (n = 2245) 24+ months follow-upa (n = 1535)
Predictors of subsequent treatment (receiving LOT2+ vs. only LOT1) Odds ratiob (95% CI) P-valueb Odds ratiob (95% CI) P-valueb Odds ratiob (95% CI) P-valueb Odds ratiob (95% CI) P-valueb
Age at MM diagnosis, years
 < 65 1.05 (0.87–1.27) 0.5989 1.13 (0.92–1.38) 0.2421 1.30 (1.03–1.65) 0.0288 1.40 (1.02–1.91) 0.0380
 65–74 Reference Reference Reference Reference
 75–84 1.21 (0.69–2.12) 0.5059 1.00 (0.57–1.77) 0.9953 1.11 (0.55–2.23) 0.7656 0.75 (0.34–1.67) 0.4855
 ≥ 85
Sex, male 1.20 (1.00–1.44) 0.0543 1.18 (0.97–1.45) 0.1029 1.18 (0.93–1.49) 0.1650 1.27 (0.94–1.73) 0.1218
Comorbidities during 180 days prior to index MM diagnosis
 Cardiovascular disordersc 0.85 (0.68–1.08) 0.1790 0.86 (0.67–1.11) 0.2423 0.88 (0.66–1.17) 0.3664 0.99 (0.68–1.45) 0.9528
 Liver disease 0.56 (0.39–0.81) 0.0017 0.49 (0.34–0.70) 0.0001 0.48 (0.31–0.73) 0.0005 0.41 (0.23–0.72) 0.0020
 Pulmonary circulation disorders 0.70 (0.39–1.27) 0.2466 0.60 (0.33–1.09) 0.0926 0.51 (0.26–1.01) 0.0520 0.36 (0.14–0.90) 0.0281
 Renal impairment 0.79 (0.62–1.02) 0.0668 0.71 (0.54–0.92) 0.0099 0.74 (0.55–1.01) 0.0601 0.58 (0.40–0.86) 0.0059
  1. CI Confidence interval, LOT Line of therapy, MM Multiple myeloma
  2. aMonths of follow-up were calculated from the start of the first line of treatment until either the end of insurance eligibility (for SEER and OPTUM™ Commercial)
  3. bOdds ratios and p-values were computed using a logistic regression
  4. cCardiovascular disorders include cardiac arrythmia, congestive heart failure, complicated hypertension, and valvular disease
\